BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China · Delayed Price · Currency is CNY 92.73
+0.02 (0.02%)
At close: Sep 12, 2025
SHA:688166 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Net Income | 99.98 | 189.17 | 202.47 | 239.62 | 243.95 | 169.88 | Upgrade |
Depreciation & Amortization | 138.3 | 109.94 | 78.06 | 50.47 | 41.5 | 30.2 | Upgrade |
Other Amortization | 11.27 | 10.66 | 10.54 | 11.09 | 10.83 | 9.04 | Upgrade |
Loss (Gain) From Sale of Assets | - | - | - | -0.01 | -0.01 | - | Upgrade |
Asset Writedown & Restructuring Costs | 9.11 | 8.39 | 1.75 | 1.57 | 0.26 | 0.27 | Upgrade |
Loss (Gain) From Sale of Investments | 10.86 | 11.97 | 12.41 | -3 | -10.02 | -3.59 | Upgrade |
Provision & Write-off of Bad Debts | 4.51 | 11.57 | 0.9 | -2.23 | 10.11 | -0.81 | Upgrade |
Other Operating Activities | 18.87 | 20.46 | 37.19 | -1.08 | 8.27 | 21.75 | Upgrade |
Change in Accounts Receivable | -33.38 | -149.93 | -17.85 | 4.96 | -241.94 | -50.51 | Upgrade |
Change in Inventory | -55.25 | -35.55 | -85.77 | -94.94 | -6.25 | -75.71 | Upgrade |
Change in Accounts Payable | 29.58 | 84.4 | -23.61 | 130.2 | 116.92 | 47.33 | Upgrade |
Change in Other Net Operating Assets | 0.17 | 15.75 | -2.96 | -21.31 | 4.16 | 11.65 | Upgrade |
Operating Cash Flow | 207.95 | 245.56 | 194.77 | 311.26 | 176.08 | 155.43 | Upgrade |
Operating Cash Flow Growth | -29.32% | 26.08% | -37.43% | 76.78% | 13.28% | 153.42% | Upgrade |
Capital Expenditures | -392.84 | -257.2 | -403.76 | -726.73 | -909.66 | -355.27 | Upgrade |
Sale of Property, Plant & Equipment | 0.32 | 0.3 | 0.48 | 0.38 | 0.05 | 0.01 | Upgrade |
Cash Acquisitions | - | - | - | 0.01 | -7.5 | - | Upgrade |
Investment in Securities | -152.05 | -228.61 | -64.24 | -153.38 | 8.64 | -218.46 | Upgrade |
Other Investing Activities | 8.87 | 45.37 | 31.26 | 18.24 | 18.64 | 31.79 | Upgrade |
Investing Cash Flow | -535.7 | -440.14 | -439.85 | -871.58 | -889.84 | -541.92 | Upgrade |
Long-Term Debt Issued | - | 823.08 | 678.23 | 1,646 | 882.2 | 234.89 | Upgrade |
Total Debt Issued | 803.91 | 823.08 | 678.23 | 1,646 | 882.2 | 234.89 | Upgrade |
Long-Term Debt Repaid | - | -804.81 | -569.61 | -474.12 | -210.88 | -15.06 | Upgrade |
Total Debt Repaid | -867.47 | -804.81 | -569.61 | -474.12 | -210.88 | -15.06 | Upgrade |
Net Debt Issued (Repaid) | -63.55 | 18.27 | 108.62 | 1,172 | 671.32 | 219.83 | Upgrade |
Issuance of Common Stock | - | - | - | 219.81 | - | - | Upgrade |
Repurchase of Common Stock | - | -10.01 | - | - | - | - | Upgrade |
Common Dividends Paid | -172.12 | -135.73 | -115.01 | -100.1 | -54.3 | -35.4 | Upgrade |
Other Financing Activities | 339.62 | 103 | 68 | 73 | 86.7 | 1.3 | Upgrade |
Financing Cash Flow | 103.94 | -24.47 | 61.61 | 1,365 | 703.72 | 185.73 | Upgrade |
Foreign Exchange Rate Adjustments | 6.51 | 2.12 | 2.78 | 14.15 | 3.72 | -13.03 | Upgrade |
Net Cash Flow | -217.29 | -216.94 | -180.69 | 818.52 | -6.32 | -213.79 | Upgrade |
Free Cash Flow | -184.89 | -11.64 | -209 | -415.47 | -733.59 | -199.84 | Upgrade |
Free Cash Flow Margin | -15.91% | -0.91% | -17.72% | -40.84% | -69.71% | -25.45% | Upgrade |
Free Cash Flow Per Share | -0.44 | -0.03 | -0.49 | -1.01 | -1.80 | -0.48 | Upgrade |
Cash Income Tax Paid | 12.72 | 25.46 | 29.42 | -17.03 | -7.18 | -10.16 | Upgrade |
Levered Free Cash Flow | 406.56 | -65.73 | -316.64 | -515.42 | -785.87 | -241.66 | Upgrade |
Unlevered Free Cash Flow | 440.24 | -32.96 | -288.87 | -500.6 | -779.81 | -240.38 | Upgrade |
Change in Working Capital | -84.94 | -116.59 | -148.54 | 14.83 | -128.81 | -71.31 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.